Clinical Trial

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well pembrolizumab works in treating patients with prostate cancer that has spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels despite previous treatment with enzalutamide. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells.
Protocol Amendment History 24 amendments
This ClinicalTrials.gov record has been amended 24 times since 2014-12-04; most recent amendment 2026-04-30.
Status change: Recruiting → Active, Not Recruiting 2018-07-18
Status change: Active, Not Recruiting → Recruiting 2017-02-10
Status change: Recruiting → Active, Not Recruiting 2016-09-20
Status change: Not Yet Recruiting → Recruiting 2015-01-05
Trial Details
NCT Number NCT02312557
Lead Sponsor OHSU Knight Cancer Institute
Collaborators: Merck Sharp & Dohme LLC, Collins Medical Trust, Oregon Health and Science University
Conditions Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma Cancer AJCC v8
Enrollment 58 participants
Start Date 2014-11-18
Primary Completion 2024-08-22 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-14